СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О РОЛИ ФИЗИКО-ХИМИЧЕСКИХ ФАКТОРОВ В ПАТОГЕНЕЗЕ КАЛЬЦИЕВОГО НЕФРОЛИТИАЗА
Аннотация
В обзоре приводится анализ современных взглядов на патогенез кальциевого нефролитиаза с позиций изменений ряда физико-химических параметров, в том числе, объемов потребляемой и выделяемой жидкости, пересыщения мочи определенными солями, верхней метастабильности и др. Приводятся сведения о действии таких природных ингибиторов кристаллизации как цитрат, магний, фитат, пирофосфат, которые рассматриваются в качестве перспективных средств профилактики рецидивов мочекаменной болезни.
Об авторах
Я. Ф. Зверев
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40, тел.: (3852) 26-08-35
В. М. Брюханов
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40, тел.: (3852) 26-08-35
В. В. Лампатов
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40, тел.: (3852) 26-08-35
А. Ю. Жариков
Алтайский медицинский университет, г. Барнаул
Россия
Россия
кафедра фармакологии
656038, г.Барнаул, пр.Ленина, 40, тел.: (3852) 26-08-35
Список литературы
1. Hess B. Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi. Ther Umsch 2003; 60 (2): 79-87
2. Reynolds TM. Chemical pathology, clinical investigation and management of nephrolithiasis. J Clin Pathol 2005; 58 (2): 134-140
3. Тиктинский ОЛ, Александров ВП. Мочекаменная болезнь. Питер, СПб., 2000; 53-91
4. Кадыров ЗА, Истратов ВГ, Сулейманов СИ. Некоторые вопросы этиологии и патогенеза мочекаменной болезни. Урология 2006; (5): 98-101
5. Heilberg IP, Schor N. Renal stone disease: causes, evaluation and medical treatment. Arq Bras Endocrinol Metab 2006; 50 (4): 823-831
6. Lingeman J, Kahnoski R, Mardis H et al. Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol 1999; 161 (4): 1077-1081
7. Pak CY. Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest 1969; 48 (10): 1914-1922
8. Pak CY, Holt K. Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. Metabolism 1976; 25 (6): 665-673
9. Brown CM, Purich DL. Physical-chemical processes in kidney stone formation. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. Raven Press, New York, 1992; 613-624
10. Asplin JR, Bushinsky DA, Singharetnam W et al. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int 1997; 51 (3): 640-645
11. Nicar MJ, Hill K, Pak CY. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism 1983; 32 (9): 906-910
12. Bushinsky DA, Parker WR, Asplin JR. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2000; 57: 550-560
13. Tiselius HG. Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule. Urol Res 1997; 25 (2): 153-159
14. Toblli JE, Angerosa M, Stella I et al. Urinary calcium oxalate supersaturation beyond nephrolithiasis. Relationship with tubulointerstitial damage. Medicina (B. Aires) 2003; 63 (2): 97-104
15. Robertson WG. Kidney models of calcium oxalate stone formation. Nephron Physiol 2004; 98 (2): 21-30
16. Pak CY, Eanes ED, Puskin B. Spontaneous precipitation of brushite in urine: evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Natl Acad Sci USA 1971; 68 (7): 1456-1460
17. Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 1978; 13 (5): 344-360
18. Carvalho M, Vieira MA. Changes in calcium oxalate crystal morphology as a function of supersaturation. Int Braz J Urol 2004; 30 (3): 205-209
19. Burns JR, Finlayson B. Changes in calcium oxalate morphology as function of concentration. Invest Urol 1980; 18 (2): 174-177
20. Parks JH, Coward M, Coe FL. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 1997; 51 (3): 894-900
21. Asplin JR, Parks J, Lingeman J et al. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol 1998; 159 (6): 1821-1825
22. Pak CY, Galosy RA. Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med 1980; 69 (5): 681-689
23. Bushinsky DA, Asplin JR, Grynpas MD et al. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2002; 61 (3): 975-987
24. Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 1997; 52 (6): 1602-1608
25. Bushinsky DA. Nephrolithiasis: site of the initial solid phase. J Clin Invest 2003; 111 (5): 602-605
26. Asplin JR, Parks JH, Chen MS et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999; 56: 1505-1516
27. Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 2002; 61: 1821-1829
28. Зверев ЯФ, Брюханов ВМ, Талалаева ОС и др. О роли процессов свободно-радикального окисления в развитии экспериментального нефролитиаза. Нефрология 2008; 12 (1): 58-63
29. Брюханов ВМ, Зверев ЯФ, Лампатов ВВ и др. Функция почек в условиях экспериментального оксалатного нефролитиаза. Нефрология 2008; 12 (1): 69-74
30. Borghi L, Guerra A, Meschi T et al. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int 1999; 55: 1041-1050
31. Borghi L, Meschi T, Amato F et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155 (3): 839-843
32. Bellizzi V, De Nicola L, Minutolo R et al. Effects of water hardness on urinary risk factors for kidney stones in patients with idiopathic nephrolithiasis. Nephron 1999; 81 (1): 66-70
33. Borghi L, Meschi T, Schianchi T et al. Urine volume: stone risk factor and preventive measure. Nephron 1999; 81 (1): 31-37
34. Whitson PA, Pietrzyk RA, Morukov BV, Sams CF. The risk of renal stone formation during and after long duration space flight. Nephron 2001; 89 (3): 264-270
35. Pietrzyk RA, Jones JA, Sams CF, Whitson PA. Renal stone formation among astronauts. Aviat Space Environ Med 2007; 78 (4): A9-A13
36. Whitson PA, Pietrzyk RA, Sams CF. Urine volume and its effects on renal stone risk in astronauts. Aviat Space Environ Med 2001; 72 (4): 368-372
37. Guerra A, Allegri F, Meschi T et al. Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load. Clin Chem Lab Med 2005; 43 (6): 585-589
38. Guerra A, Meschi T, Allegri F et al. Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 2006; 34 (6): 359-364
39. Parks JH, Goldfischer ER, Coe FL. Changes in urine volume accomplished by physicians treating nephrolithiasis. J Urol 2003; 169 (3): 863-866
40. Stitchantrakul W, Kochakarn W, Ruangraksa C, Domrangkitchaiporn S. Urinary risk factors for recurrent calcium stone formation in Thai stone formers. J Med Assoc Thai 2007; 90 (4): 688-698
41. Ratan SK, Bhatnagar V, Mitra DK et al. Urinary citrate excretion in idiopathic nephrolithiasis. Indian Pediatrics 2002; 39: 819-825
42. Tiselius HG, Berg C, Fornander AM, Nilsson MA. Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 1993; 7 (1): 381-389
43. Pak CY, Poindexter JR, Adams-Huet B, Pearle MS. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003; 115 (1): 26-32
44. Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis 2006; 48 (4): 546-554
45. Chow K, Dixon J, Gilpin S et al. Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int 2004; 65 (5): 1724-1730
46. Hess B, Jordi S, Zipperle L et al. Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 2000; 15 (3): 366-374
47. Schwille PO, Schmied A, Manoharan M. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein. Clin Chem Lab Med 2004; 42 (3): 283-293
48. Kulaksizoglu S, Sofikerim M, Cevik C. Impact of various modifiers on calcium oxalate crystallization. Int J Urol 2007; 14 (3): 214-218
49. Hшjgaard I, Tiselius HG. The effects of citrate and urinary macromolecules on the aggregation of hydroxyapatite crystals in solutions with a composition similar to that in the distal tubule. Urol Res 1998; 26 (2): 89-95
50. Greischar A, Nakagawa Y, Coe FL. Influence of urine pH and citrate concentration on the upper limit of metastability for calcium phosphate. J Urol 2003; 169 (3): 867-870
51. Messa P, Mioni G, Paganin L et al. Urinary citrate, bone resorption and intestinal alkali absorption in stone formers with fasting hypercalciuria. Scanning Microsc 1994; 8 (3): 531-538
52. Berg C. Alkaline citrate in prevention of recurrent calcium oxalate stones. Scand J Urol Nephrol Suppl 1990; 130: 1-83
53. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115 (10): 2598-2608
54. Hassani MA, Hennequin C, Lacour B, Daudon M. Influence of urinary citrate levels on spontaneous calcium oxalate dehydrate crystalluria. Prog Urol 2005; 15 (4): 650-655
55. Kok DJ, Papapoulos SE, Blomen LJMJ, Bijvoet OLM. Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 1988; 34: 346-350
56. Hennequin C, Lalanne V, Drueke T et al. Validation by image analysis of a turbidimetric method to study calcium oxalate crystallization. Clin Nephrol 1997; 48: 292-299
57. Byer K, Khan SR. Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 2005; 173 (2): 640-646
58. Weber DV, Coe FL, Parks JH, Tembe V. Urinary saturation measurements in calcium nephrolithiasis. Am Int Med 1979; 90: 180-184
59. Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31 (4): 885-893
60. Allie-Hamdulay S, Rodgers A. Prophylactic and therapeutic properties of a sodium citrate preparation for the potential management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 2005; 33: 116-124
61. Rodgers A, Allie-Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant 2006; 21 (2): 361-369
62. Qiu SR, Wierzbicki A, Orme CA et al. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 2004; 101 (7): 1811-1815
63. Qiu SR, Wierzbicki A, Salter EA et al. Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. J Am Chem Soc 2005; 127 (25): 9036-9044
64. De Yoreo JJ, Qiu SR, Hoyer JR. Molecular modulation of calcium oxalate crystallization. Am J Physiol Renal Physiol 2006; 291 (6): F1123-F1131
65. Cupisti A, Morelli E, Lupetti S et al. Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 1992; 61: 73-76
66. Yagisawa T, Chandhoke PS, Fan J. Metabolic risk factors in patients with first-time and recurrent stone formations as determined by comprehensive metabolic evaluation. Urology 1998; 52: 750-755
67. Fegan J, Khan SR, Poindexter J, Pak CY. Gastrointestinal citrate absorption in nephrolithiasis. J Urol 1992; 147: 1212-1214
68. Hamm LL. Renal handling of citrate. Kidney Int 1990; 38: 728-735
69. Pajor CY. Citrate transport by the kidney and intestine. Semin Nephrol 1999; 19: 195-200
70. He Y, Chen X, Yu Z et al. Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis. J Nephrol (JN)2004; 17 (1): 34-42
71. Okamoto N, Aruda S, Matsuzaki S et al. Association between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol 2007; 14 (4): 344-349
72. Спасов АА. Магний в медицинской практике. Отрок, Волгоград, 2006; 34-56
73. Labeeuw M, Pozet N, Zech P, Traeger J. Role of magnesium in the physiopathology and treatment of calcium renal lithiasis. Presse Med 1987; 16 (1): 25-27
74. Johansson G, Backman U, Danielson BG et al. Effects of magnesium hydroxide in renal stone disease. J Am Cell Nutr 1982; 1 (2): 179-185
75. Vagelli G, Calabrese G, Pratesi G et al. Magnesium hydroxide in idiopathic calcium nephrolithiasis. Minerva Urol Nefrol 1998; 50 (1): 113-114
76. Rushton HG, Spector M. Effects of magnesium deficiency on intratubular calcium oxalate formation and crystalluria in hyperoxaluric rats. J Urol 1982; 127 (3): 598-604
77. Спасов АА, Иежица ИН, Харитонова МВ и др. Экспериментальное обоснование эффективности солей магния в коррекции экспериментального кальций-фосфатного нефролитиаза. Нефрология 2008; 12 (3): 72-78
78. Lieske JC, Farell G, Deganello S. The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. Urol Res 2004; 32 (2): 117-123
79. Fetner CD, Barilla DE, Townsend J, Pak CY. Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis. J Urol 1978; 120 (4): 399-401
80. Schwartz BF, Bruce J, Lesile S, Stoller ML. Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol 2001; 15 (3): 233-235
81. Massey L. Magnesium therapy for nephrolithiasis. Magnesium Res 2005; 18 (2): 123-126
82. Schwille PO, Schmiedl A, Herrmann U et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 1999; 27 (2): 117-126
83. Jaipakdu S, Prasongwatana V, Premgamone A et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. J Med Assoc Thai 2004; 87 (3): 255-263
84. Zerwekh JE, Odvina CV, Wuermser LA, Pak CY. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest. J Urol 2007; 177 (6): 2179-2184
85. Grases F, Costa-Bauza A. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res 1999; 19 (5A): 3717-3722
86. Grases F, March JG, Prieto RM et al. Urinary phytate in calcium oxalate stone formers and healthy people-dietary effects on phytate excretion. Scand J Urol Nephrol 2000; 34 (3): 162-164
87. Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A. Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 1998; 32 (4): 261-265
88. Grases F, Isern B, Sanchis P et al. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 2007; 12: 2580-2587
89. Saw NK, Chow K, Rao PN, Kavanagh JP. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth. J Urol 2007; 177 (6): 2366-2370
90. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962; 203: 671-675
91. Moochhala SH, Sayer JA, Carr G, Simmons NL. Renal calcium stones: insights from the control of bone mineralization. Exp Physiol 2008; 93 (1): 43-49
92. Russell RG. Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 1976; 19 (3): 465-478
93. Laminski NA, Meyers AM, Sonnekus MI, Smyth AE. Prevalence of hypocitraturia and hypopyrophosphaturia in recurrent calcium stone formers: as isolated defects or associated with other metabolic abnormalities. Nephron 1990; 56: 379-386
94. Baumann JM, Bisaz S, Felix R et al. The role of inhibitors and other factors in the pathogenesis of recurrent calcium-containing renal stones. Clin Sci Mol Med 1977; 53: 141-148
95. Wikstrom B, Danielson BG, Ljunghall S et al. Urinary pyrophosphate excretion in renal stone formers with normal and impaired renal acidification. World J Urol 1983; 1: 150-154
96. Roberts NB, Dutton J, Helliwell T et al. Pyrophosphate in synovial fluid and urine and its relationship to urinary risk factors for stone disease. Ann Clin Biochem 1992; 29: 529-534
97. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269-280
98. Grases F, Ramis M, Costa-Bauza A. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates. Urol Res 2000; 28 (2): 136-140
99. March JG, Simonet BM, Grases F. Determination of pyrophosphate in renal calculi and urine by means of an enzymatic method. Clin Chim Acta 2001; 314: 187-194
100. Costa-Bauza A, Barcelo C, Perello J, Grases F. Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors. Int Urol Nephrol 2002; 34: 447-451
101. Nouwen EJ, De Broe ME. Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney Int Suppl 1994; 47: S43-S51
102. Harahap AR, Goding JW. Distribution of the murine plasma cell antigen PC-1 in non-lymphoid tissues. J Immunol 1988; 141: 2317-2320
103. Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase / phosphodiesterase family. Biochim Biophys Acta 2003; 1638: 1-19
104. Vekaria RM, Shirley DG, Sevigny J, Unwin RJ. Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 2006; 290: F550-F560
105. Vekaria RM, Unwin RJ, Shirley DG. Intraluminal ATP concentrations in rat renal tubules.J Am Soc Nephrol 2006; 17: 1841-1847
106. Carr G, Sayer JA, Simmons NL. Expression and localization of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem 2007; 20: 507-516
107. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289: 265-270
108. Arrabal MM, Diaz de la Guardia FV, Jimenez PA et al. The treatment of renal lithiasis with biphosphonates. Arch Esp Urol 2007; 60 (7): 745-754
109. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturateion in genetic hypercalciuric rats. Kidney Int 1999; 55 (1): 234-243
Для цитирования:
Зверев Я.Ф., Брюханов В.М., Лампатов В.В., Жариков А.Ю. СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О РОЛИ ФИЗИКО-ХИМИЧЕСКИХ ФАКТОРОВ В ПАТОГЕНЕЗЕ КАЛЬЦИЕВОГО НЕФРОЛИТИАЗА. Нефрология. 2009;13(1):39-50. https://doi.org/10.24884/1561-6274-2009-13-1-39-50
For citation:
Zverev Y.P., Bryukhanov V.M., Lampatov V.V., Jaricov A.Yu. THE CURRENT VIEWS ON THE ROLE OF PHYSICO-CHEMICAL FACTORS IN PATHOGENESIS OF CALCIUM NEPHROLYTHIASIS. Nephrology (Saint-Petersburg). 2009;13(1):39-50. (In Russ.) https://doi.org/10.24884/1561-6274-2009-13-1-39-50
Просмотров: 69
Послать статью по эл. почте 